Drug Trial Radar · NCT00915525
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Last checked: Nov 20, 2026Latest source record: Apr 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
829
Actual
Start
Feb 1, 2010
Primary completion
Aug 5, 2014
Study completion Aug 5, 2014
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 8, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
Conditions
- Overactive Bladder
- Urinary Incontinence
Interventions
botulinum toxin Type ABiological
Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 1
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 2
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 3
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 4
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 5
- Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 6
- Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)Time frame: Week 12 Treatment Cycle 1
- Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 2
- Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 3
- Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 4
- Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 5
- Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 6
Locations
8 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Newport Beach, California
Site not named
Ghent, Belgium
Site not named
Victoria, British Columbia, Canada
Site not named
Prague, Czechia
Site not named
Tübingen, Germany
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.